正典 片岡
代表取締役
NATiAS Inc.
The startup develops nucleic acid-based adjuvants and primers for PCR genetic testing, utilizing blocker-based oligonucleotide synthesis technology to produce high-purity oligonucleotides at scale. This capability enables pharmaceutical companies to enhance the development of therapeutics by providing reliable and efficient nucleic acid APIs.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
The production of nucleic acid-based therapeutics and diagnostics is often hampered by inefficient synthesis methods that yield lower purity oligonucleotides and require extensive purification, increasing costs and development timelines. Traditional monomer-based synthesis can result in impurities, such as shorter chain lengths, which can affect the efficacy and safety of the final product.
Solution
NATiAS Inc. offers a suite of nucleic acid products and contract manufacturing services leveraging its proprietary Blockmer® technology to streamline oligonucleotide synthesis and produce high-purity nucleic acid APIs. Blockmer® technology significantly shortens the synthesis process compared to conventional methods, enabling faster production and reduced costs. By using pre-synthesized blocks of nucleotides, NATiAS minimizes the formation of truncated sequences and other impurities, resulting in highly defined and consistent oligonucleotide products. The company provides custom oligonucleotide synthesis services, as well as a catalog of Blockmer® reagents and CpG ODN adjuvants. NATiAS's GMP manufacturing capabilities support the development of nucleic acid-based therapeutics from early-stage research to commercialization.
Target Audience
NATiAS serves pharmaceutical and biotechnology companies involved in developing nucleic acid-based therapeutics, diagnostics, and vaccines, as well as research institutions requiring high-quality oligonucleotides.
Features
- Blockmer® technology for accelerated oligonucleotide synthesis
- High-purity nucleic acid APIs with minimal truncated sequences
- Customizable Blockmer® reagents with diverse structural options
- Contract manufacturing services for nucleic acid-based therapeutics and diagnostics
- CpG ODN adjuvants for vaccine development and immunotherapy
- GMP-compliant manufacturing and quality control
- Capabilities for both solid-phase and liquid-phase synthesis